Adverum Bio (ADVM) Revenue & Revenue Breakdown
Adverum Bio Revenue Highlights
Latest Revenue (Y)
$1.00M
Main Segment (Y)
Reportable Segment
Adverum Bio Revenue by Period
Adverum Bio Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $1.00M | -72.22% |
| 2023-12-31 | $3.60M | 100.00% |
| 2022-12-31 | - | -100.00% |
| 2021-12-31 | $7.50M | 100.00% |
| 2020-12-31 | - | -100.00% |
| 2019-12-31 | $250.00K | -84.49% |
| 2018-12-31 | $1.61M | -12.82% |
| 2017-12-31 | $1.85M | 27.08% |
| 2016-12-31 | $1.46M | -37.26% |
| 2015-12-31 | $2.32M | 305.42% |
| 2014-12-31 | $572.00K | 19.17% |
| 2013-12-31 | $480.00K | 1500.00% |
| 2012-12-31 | $30.00K | - |
Adverum Bio generated $1.00M in revenue during NA 2024, up -72.22% compared to the previous quarter, and up 400.00% compared to the same period a year ago.
Adverum Bio Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-03-31 | - | -100.00% |
| 2024-12-31 | $-3.60M | -460.00% |
| 2024-09-30 | $1.00M | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $-3.60M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | -100.00% |
| 2023-03-31 | $3.60M | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | -100.00% |
| 2021-12-31 | $-7.50M | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | -100.00% |
| 2021-03-31 | $7.50M | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | -100.00% |
| 2019-12-31 | $-250.00K | -200.00% |
| 2019-09-30 | $250.00K | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | -100.00% |
| 2018-12-31 | $70.00K | -91.60% |
| 2018-09-30 | $833.00K | 68.97% |
| 2018-06-30 | $493.00K | 128.24% |
| 2018-03-31 | $216.00K | -53.15% |
| 2017-12-31 | $461.00K | -0.43% |
| 2017-09-30 | $463.00K | - |
| 2017-06-30 | $463.00K | 0.22% |
| 2017-03-31 | $462.00K | -5.33% |
| 2016-12-31 | $488.00K | 23.54% |
| 2016-09-30 | $395.00K | 28.66% |
| 2016-06-30 | $307.00K | 15.85% |
| 2016-03-31 | $265.00K | -72.40% |
| 2015-12-31 | $960.00K | 0.73% |
| 2015-09-30 | $953.00K | 369.46% |
| 2015-06-30 | $203.00K | - |
| 2015-03-31 | $203.00K | - |
| 2014-12-31 | $203.00K | -0.49% |
| 2014-09-30 | $204.00K | 51.11% |
| 2014-06-30 | $135.00K | 350.00% |
| 2014-03-31 | $30.00K | 100.00% |
| 2013-12-31 | - | -100.00% |
| 2013-09-30 | $30.00K | -80.00% |
| 2013-06-30 | $150.00K | -50.00% |
| 2013-03-31 | $300.00K | - |
Adverum Bio generated - in revenue during Q1 2025, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Adverum Bio Revenue Breakdown
Adverum Bio Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 |
|---|---|
| Reportable Segment | $1.00M |
Latest
Adverum Bio's latest annual revenue breakdown by segment (product or service), as of Dec 24: Reportable Segment (100.00%).
Adverum Bio Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| SRZN | Surrozen | $10.65M | $983.00K |
| SPRB | Spruce Biosciences | $4.91M | - |
| ORMP | Oramed Pharmaceuticals | $1.34M | - |
| ADVM | Adverum Bio | $1.00M | - |
| ATYR | aTyr Pharma | $353.00K | - |
| GUTS | Fractyl Health | $120.00K | - |
| ALXO | ALX Oncology | - | - |
| ACET | Adicet Bio | - | - |
| KLRS | Kalaris Therapeutics | - | - |
| PLRX | Pliant Therapeutics | - | - |
| BMEA | Biomea Fusion | - | - |